A Novel Ruthenium Based Coordination Compound Against Pathogenic Bacteria.

Area of Science:

• Coordination Chemistry
• Microbiology
• Materials Science

Background:

• The rise of antibiotic-resistant infections necessitates the development of novel therapeutic agents.
• Ruthenium-based compounds are being explored for their potential antimicrobial properties.

Purpose of the Study:

• To synthesize and characterize a novel ruthenium-Schiff base-benzimidazole coordinate compound, designated RU-S4.
• To evaluate the antibacterial efficacy of RU-S4 against various strains of Staphylococcus, including antibiotic-resistant variants.
• To assess the in vivo efficacy and toxicity of RU-S4.

Main Methods:

• Synthesis of RU-S4 using ruthenium chloride and a Schiff base-benzimidazole ligand.
• Characterization using scanning electron microscopy (SEM), energy-dispersive X-ray spectroscopy (EDS), and Raman spectroscopy.
• Antibacterial activity assessed via growth curve analysis, optical microscopy, and fluorescence LIVE/DEAD cell imaging against Staphylococcus aureus, VRSA, MRSA, and Staphylococcus epidermidis.
• In vivo efficacy tested on a balb/c mice model infected with VRSA.
• Cytotoxicity evaluated on mammalian cells and in vivo.

Main Results:

• RU-S4 was successfully synthesized and characterized.
• The compound demonstrated significant antibacterial activity against all tested Staphylococcus strains, including MRSA and VRSA.
• Growth curve analysis and cell imaging confirmed the bactericidal effect of RU-S4.
• Complete cure was observed in VRSA-infected mice treated with RU-S4.
• RU-S4 exhibited no toxicity towards mammalian cells or in vivo.

Conclusions:

• The novel coordinate compound RU-S4 possesses strong antibacterial properties against clinically relevant Staphylococcus strains.
• RU-S4 demonstrates excellent in vivo efficacy and a favorable safety profile, making it a promising candidate for further development as an antibiotic alternative.